Cargando…

Challenges of NTM Drug Development

Discovery and development of antibiotics active against the environmental opportunistic non-tuberculous mycobacteria (NTM) have been retarded by innate antibiotic-resistance of NTM cells and methodological challenges in the laboratory. The basis for the innate resistance of NTM cells is its lipid ri...

Descripción completa

Detalles Bibliográficos
Autor principal: Falkinham, Joseph O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058048/
https://www.ncbi.nlm.nih.gov/pubmed/30072975
http://dx.doi.org/10.3389/fmicb.2018.01613
_version_ 1783341625332727808
author Falkinham, Joseph O.
author_facet Falkinham, Joseph O.
author_sort Falkinham, Joseph O.
collection PubMed
description Discovery and development of antibiotics active against the environmental opportunistic non-tuberculous mycobacteria (NTM) have been retarded by innate antibiotic-resistance of NTM cells and methodological challenges in the laboratory. The basis for the innate resistance of NTM cells is its lipid rich outer membrane that results in hydrophobic cells and the outer membrane’s impermeability, and the residence of NTM cells in phagocytic cells, and the slow growth and dormancy of NTM. Laboratory challenges include: the choice of species and strains for screening and measurement of anti-NTM activity, the high frequency colony switching between antibiotic-susceptible and resistant variants, the preference of NTM to adhere to surfaces and form biofilms, and the aggregation of NTM cells. Understanding these challenges can guide and inform our approaches to discovery and development of antibiotics with activity against NTM.
format Online
Article
Text
id pubmed-6058048
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60580482018-08-02 Challenges of NTM Drug Development Falkinham, Joseph O. Front Microbiol Microbiology Discovery and development of antibiotics active against the environmental opportunistic non-tuberculous mycobacteria (NTM) have been retarded by innate antibiotic-resistance of NTM cells and methodological challenges in the laboratory. The basis for the innate resistance of NTM cells is its lipid rich outer membrane that results in hydrophobic cells and the outer membrane’s impermeability, and the residence of NTM cells in phagocytic cells, and the slow growth and dormancy of NTM. Laboratory challenges include: the choice of species and strains for screening and measurement of anti-NTM activity, the high frequency colony switching between antibiotic-susceptible and resistant variants, the preference of NTM to adhere to surfaces and form biofilms, and the aggregation of NTM cells. Understanding these challenges can guide and inform our approaches to discovery and development of antibiotics with activity against NTM. Frontiers Media S.A. 2018-07-18 /pmc/articles/PMC6058048/ /pubmed/30072975 http://dx.doi.org/10.3389/fmicb.2018.01613 Text en Copyright © 2018 Falkinham. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Falkinham, Joseph O.
Challenges of NTM Drug Development
title Challenges of NTM Drug Development
title_full Challenges of NTM Drug Development
title_fullStr Challenges of NTM Drug Development
title_full_unstemmed Challenges of NTM Drug Development
title_short Challenges of NTM Drug Development
title_sort challenges of ntm drug development
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058048/
https://www.ncbi.nlm.nih.gov/pubmed/30072975
http://dx.doi.org/10.3389/fmicb.2018.01613
work_keys_str_mv AT falkinhamjosepho challengesofntmdrugdevelopment